Nanotechnology In Drug Delivery - Global Strategic Business Report

Nanotechnology In Drug Delivery - Global Strategic Business Report

Global Industry Analysts, Date of Publication: Feb 13, 2014, 202 Pages
US$4,950.00
GIA-MCP7808
This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research.  The report profiles 60 companies including many key and niche players such as -

Access Pharmaceuticals, Inc.
Alkermes PLC
Aquanova AG
Camurus AB
Capsulution Pharma AG
Celgene, Inc.

More information can be obtained upon the request of sample pages.


TABLE OF CONTENTS

 I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-2
      Product Definitions and Scope of Study                            I-3
       Nanotechnology and Nanomedicine                                  I-3
       Nanotechnology in Drug Delivery                                  I-3
       Nanotechnology Drug Delivery Systems                             I-3
        Nanocrystals                                                    I-3
        Nanocarriers                                                    I-3


 II. EXECUTIVE SUMMARY

  1. OUTLOOK                                                            II-1
      Nanotechnology - the Next Big Thing in Drug Development           II-1
      Present Status and Opportunities that Lie Ahead                   II-2
      Current & Future Analysis                                         II-2
      Major Market Drivers                                              II-3
      Nanocrystals Outperform Nanocarriers                              II-3
      Liposomes - Leading the Way                                       II-3
      Dendrimers Serve as a Base to Build Multifunctional Nanodevices   II-4

  2. INDUSTRY OVERVIEW                                                  II-5
      Nanotechnology - An Introduction                                  II-5
       Impact of Nanotechnology in a Nutshell                           II-5
      How Does Nanotechnology Help Drug Delivery?                       II-6
       Drug Delivery Technologies - A Fast Rising Market                II-6
       Select Key Requirements for Development of Advanced Drug
        Delivery Systems                                                II-6
      Drug Delivery - A Key Application of Nanotechnology in Medicine   II-7
       Major Milestones in the Evolution of Nanotechnology- based
        Drug Delivery Materials                                         II-8
       Table 1: Global Nanomedicine market by Application:
       Percentage Breakdown of the Market for Drug Delivery,
       Implants, In vivo Diagnostics and In vitro Diagnostics
       (includes corresponding Graph/Chart)                             II-8
      Nanotechnology Rescues Poor Water Soluble Drugs from Abandonment  II-8
      Nanotechnology Promises to Play Enabling Role in Delivery of
       New Therapeutics                                                 II-10
      The Need for Targeted Delivery                                    II-10
       The Difficulty in Clinical Use of Targeted Delivery              II-11
      NEM Devices as Drug Delivery Vehicles                             II-11
      Nanotechnology - In Pursuit of Co-Delivery of Drugs               II-12
      Nanoparticles in Minimizing or Averting Multi-Drug Resistance     II-12
      Nanoscale Devices Enable Delivery of Multi-functional
       Therapeutics                                                     II-13
      Theranostics - A Potential Application of Nanotechnology-based
       Co-Delivery                                                      II-13
      Nanoemulsions Begin to Make a Mark                                II-13
       Growing Application of Nanoemulsions                             II-14
        A Review of Select Investigational Nanoemulsion Formulations    II-14

  3. TRENDS & ISSUES                                                    II-16
      Tough Market Conditions Drive Interest in Nanotechnology-Based
       Drug Delivery                                                    II-16
       Table 2: Select Major Drugs Scheduled to Lose Patent
       Protection through 2013-2016: Annual Global Sales for Years
       2010 & 2011                                                      II-17

       Table 3: Number of Drugs (NMEs and NBEs) Approved by US FDA:
       2001-2012 (includes corresponding Graph/Chart)                   II-18

       Table 4: Number of Drugs (NMEs and NBEs) Approved by European
       Medicines Agency: 2010-2012 (includes corresponding
       Graph/Chart)                                                     II-18
      Unmet Needs to Surge Interest in Nanotechnology- based Drug
       Delivery                                                         II-18
      Narrowing Drug Pipelines and Threat from Generics Raise
       Interest in Nanotechnology                                       II-19
      Size - A Critical Factor in Improving Targeting Capability        II-19
      Shape of Drug Carriers More Important than Size - A New
       Revelation                                                       II-20
      Existing Nanotechnology Drugs are Simple                          II-20
      Creation of New Therapeutics - The Next Avenue for Nanotechnology II-20
      Consumer Pull to Benefit Nanotechnology Based Drugs               II-21
      Oral Therapies to Revel from Advances in Nanotechnology           II-21
      Increasing Funding for Nanotechnology Based Therapeutics
       Development                                                      II-21
       Table 5: Global Annual Government Funding for Nanotechnology
       for Years 2003-2012 (includes corresponding Graph/Chart)         II-22
      Convergence of Enabling Technologies - A New Phase in Drug
       Delivery                                                         II-22
      Cloudy Future Threatens Advanced Drug Delivery Technologies
       with Premature Demise                                            II-23
      Increasing Environmental and Health Concerns - A Critical
       Challenge to Technological Advancement                           II-23
      Limited Success and Scaling Up Issues Pose a Major Hurdle to
       Further Advancement                                              II-24
      Financial and Economic Challenges Hurt Developmental Efforts      II-24
      Higher Concentration of Research in Academia limits
       Commercialization                                                II-24
      Collaborations Assume Importance                                  II-25
      Nano Drug Delivery to Drive Tremendous Industry Activity Going
       Ahead                                                            II-25
      Challenges to Leveraging Technological Advancements for
       Boosting Drug Delivery Efficiency                                II-25
      Nanomedicine Regulation - the Approach and the Issues Associated  II-26
      Regulations in Nanotechnology - Still Significant Room Exists
       for Improvement                                                  II-27

  4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS                    II-28
      Modern Technological Advancements Take Forward Drug Delivery
       Systems                                                          II-28
       List of Select Nanomedicines Approved by FDA                     II-28
       Select Non-targeted Nanoparticles in Drug Delivery in Mid-
        and Late-Stage Clinical Trials                                  II-30
      New Technology Enabled Depot Formulations                         II-31
      An Insight into Key Areas of Application                          II-32
       Cancer Therapy                                                   II-32
        Nanotechnology to Revolutionize Cancer Therapy                  II-32
        Nanoparticles Change Therapeutic Index of Chemotherapeutic
         Agents                                                         II-32
         List of Select Nanoparticle Drug Delivery Systems and Uses
          in Cancer Therapies                                           II-33
        A Review of Select Nanotechnology-Based Delivery Systems in
         Anti-Cancer Therapies                                          II-33
         Albumin - A Key Delivery Vehicle                               II-33
         Micellar Nanoparticle Formulation of Paclitaxel                II-34
         Liposomal Formulation of Anti-Cancer Therapies                 II-34
         Dendrimers Finding Extending Use in Nanoparticle based
          Anti-Cancer Drug Delivery                                     II-35
         Polymeric Micelles in Cancer Drug Delivery                     II-35
       Nanotechnology in Pulmonary Delivery of Drugs                    II-35
        Increasing Attention towards Pulmonary Delivery of
         Nanoparticle-Based Drugs                                       II-35
        Liposomes - The Popular Choice for Drug Delivery through Lungs  II-36
        Other Nanovehicles in Pulmonary Delivery                        II-37
        SLNs in Pulmonary Delivery of Drugs                             II-37
        Tuberculosis Treatment - A Major Application of Pulmonary
         Delivery                                                       II-38
        Nanotechnology in Infectious Disease Treatment                  II-38
         Nanotechnology Finds Increasing Role in Fighting Infectious
          Diseases                                                      II-38
        Liposomes                                                       II-39
         Liposomes - Leading the Way in Antimicrobial
          Nanotechnology-Based Drug Delivery                            II-39
         Overview of Select Liposome-Delivered Antimicrobial Products   II-39
        Polymeric Nanoparticles                                         II-40
        Solid Lipid Nanoparticles                                       II-40
        Dendrimers                                                      II-41
         List of Select Nanotechnology-based Antimicrobial Drugs in
          Clinical Use                                                  II-41
        Nanotechnology Opening New Avenues in Antiretroviral Therapy    II-43
         Demonstrated Activity of Select Nanotechnology- Delivered
          Antiretroviral Therapies                                      II-43
       Nanotechnology in Delivery of CNS Therapeutics                   II-44
        The Blood-Brain Barrier and Effectiveness of Therapeutics       II-44
        Nanoparticles Provide a Safer Means to Circumvent BBB           II-45
       Nanotechnology in Delivery of Therapeutics for Ocular Conditions II-45
        New Forms of Drug Delivery to Treat Ocular Conditions           II-45
        Efficient Drug Delivery through Micro-sized Implants            II-46
       Pain Management                                                  II-46
        Timed-release Topical Formulation Offers Pain Relief from
         Arthritis and Acute Injuries                                   II-46
         MyOmega 3 for Relief from Flares of Gouty Pain                 II-47
         MyOmega 3 Comes with Two Pain Relieving Products               II-47
         Nano-Icepearls Particles Technology - The Driver of MyOmega 3  II-48
       Polymeric Nanoparticles Promise Better Treatment for
        Childhood Leukemia                                              II-48
       Nano-immunology - Still in Nascent Stages                        II-49

  5. PRODUCT OVERVIEW                                                   II-50
      Defining Nanotechnology and Nanomedicine                          II-50
      Nanotechnology in Drug Delivery                                   II-50
       Applications of Nanoparticles in Drug Delivery                   II-50
      Nanotechnology-Based Drug Delivery Technologies by Segment        II-51
       Nanocrystals                                                     II-51
       Nanocarriers                                                     II-51
        Nanostructures in Drug Delivery                                 II-51
         Features of a Rational Nanocarrier                             II-52
         List of Select Nanomaterials Being Studied or Developed for
          Drug Delivery                                                 II-52
         Drug Delivery Technologies, Forms and Materials                II-52
        Overview of Select Major Nanocarriers                           II-53
         Comparison of Key Attributes of Select Major Nanocarriers      II-53
         Liposomes                                                      II-54
          List of Select Drugs/Compounds Demonstrated for
           Efficacious Liposome-based Delivery                          II-54
         Polymeric Nanoparticles                                        II-54
          List of Select Drugs Demonstrated for Efficacious
           Polymeric Nanoparticle-based Delivery                        II-55
         Dendrimers                                                     II-55
          List of Select Drugs Demonstrated for Efficacious
           Dendrimer-based Delivery                                     II-56
         Solid Lipid Nanoparticles (SLNs)                               II-56
         Nanotubes                                                      II-57
          List of Select Drugs Demonstrated for Efficacious
           Nanotube-based Delivery                                      II-57
         Polymeric Micelles                                             II-57
         Nanocapsules                                                   II-58
         Fullerenes                                                     II-58
      Nanostructure Synthesis                                           II-58
       Top-Down Approach                                                II-58
       Bottom-Up Approach                                               II-58
      Requisites for Optimal Nanoparticle Design                        II-59
       Size and Surface Charge of the Nanoparticle                      II-59
       PEGylation and Ligand Functionalization                          II-59

  6. RECENT INDUSTRY ACTIVITY                                           II-60
      Labtec Changes Name to tesa Labtec                                II-60
      Andain Announces Development of Drug Delivery Nano-Particles      II-60
      Bind Therapeutics Teams-up with Pfizer                            II-60
      FDA Clears Abraxis’s Abraxane for First Line Pancreatic Cancer
       Treatment                                                        II-61
      pSivida Inks Agreement to Evaluate Tethadur Protein/Antibody
       Delivery Technology                                              II-61
      Venus Medicine Research Centre to Invest in Nanotechnology
       Product Research                                                 II-61
      mPhase Files Patent for New Drug Delivery System Based on
       Smart Surface Technology                                         II-62
      Midatech Generates Funding for Development of Chemotherapeutic
       Gold Nanoparticles                                               II-62
      Galen Acquires DaunoXome® from Gilead Sciences                    II-62
      Exploit Technologies Releases New Delivery System for
       Worldwide Licensing, Partnering                                  II-63
      Celator and Cephalon Extend Research Agreement                    II-63
      Morphotek Acquires Assets of Tumor-Targeting Peptide Platform
       from TransMolecular                                              II-63
      Encap and Lena Join Forces for Developing Nano-Capsule Technology II-64
      Dolomite Unveils New Microfluidic System for Synthesis of
       Nanoparticle                                                     II-64
      Osaka Bioventure to Develop Anti-Inflammatory Transdermal
       Patch in US                                                      II-64
      Quantum Materials and Nanoaxis Form Technology Alliance           II-65
      BioAlliance Gets European Patent for Its Transdrug Nanotechnology II-65
      Kadmon and Nano Terra Form Joint Venture for Nano-Level Drug
       Delivery                                                         II-65
      Yissum Announces Successful Pre-Clinical Results for Oral
       Delivery of Docetaxel Using Nanotechnology                       II-66
      Thailand and South Korea Sign MOU for Joint Nanotechnology
       Research                                                         II-67
      IBM and Institute of Bioengineering and Nanotechnology Utilize
       Semiconductor Nanotechnology to Treat Infectious Diseases        II-67
      Camurus Enters into License Agreement with Novartis               II-67
      Flamel Technologies Inks Agreement with GlaxoSmithKline           II-68
      Eagle Pharmaceuticals Inks Development and License Agreement
       with Flamel Technologies                                         II-68
      Alkermes and Elan Drug Technologies Ink Merger Agreement          II-69
      AAIPharma and CritiTech Enter into Partnership                    II-70
      Midatech and Monosol Sign Expanded Collaboration Agreement        II-70
      Celator Receives US Patent for CombiPlex® Technology Platform     II-71
      Sosei Acquires Activus Pharma                                     II-71
      Charlesson Obtains Funding for Development of Anti-Glaucoma Drug  II-72
      Aphios Obtains US Patent for the Polymer Drug Delivery
       Nanotechnology Platform                                          II-72
      Celator to Participate in NCI's Characterization Studies for
       Nanoparticle Prodrug Delivery System                             II-73
      Celgene Takes Over Abraxis BioScience                             II-73

  7. FOCUS ON SELECT PLAYERS                                            II-74
      Access Pharmaceuticals, Inc. (US)                                 II-74
      Alkermes PLC (Ireland)                                            II-74
      Aquanova AG (Germany)                                             II-75
      Camurus AB (Sweden)                                               II-75
      Capsulution Pharma AG (Germany)                                   II-76
      Celgene, Inc. (Canada)                                            II-76
      Ceramisphere Pty Ltd. (Australia)                                 II-76
      Crititech LLC (US)                                                II-77
      EnColl Corporation (US)                                           II-77
      Enzon Pharmaceuticals, Inc. (US)                                  II-78
      Flamel Technologies SA (France)                                   II-78
      Lena Nanoceutics Ltd. (UK)                                        II-79
      NanoBio® Corporation (US)                                         II-79
      NanoCarrier Co., Ltd. (Japan)                                     II-79
      Nano Interface Technology, Inc. (US)                              II-80
      pSivida Corp. (US)                                                II-80

  8. GLOBAL MARKET PERSPECTIVE                                          II-81
      Table 6: World Recent Past, Current & Future Analysis for
      Nanotechnology in Drug Delivery by Geographic Region - US,
      Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
      America and Rest of World Markets Independently Analyzed with
      Annual Sales Figures in US$ Million for Years 2009 through
      2018 (includes corresponding Graph/Chart)                         II-81

      Table 7: World 10-Year Perspective for Nanotechnology in Drug
      Delivery by Geographic Region - Percentage Breakdown of Dollar
      Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
      Japan), Latin America and Rest of World Markets for Years
      2009, 2013 & 2018 (includes corresponding Graph/Chart)            II-82

      Table 8: World Recent Past, Current & Future Analysis for
      Nanotechnology in Drug Delivery by Technology - Nanocrystals
      and Nanocarriers Markets Independently Analyzed with Annual
      Sales Figures in US$ Million for Years 2009 through 2018
      (includes corresponding Graph/Chart)                              II-83

      Table 9: World 10-Year Perspective for Nanotechnology in Drug
      Delivery by Technology - Percentage Breakdown of Dollar Sales
      for Nanocrystals and Nanocarriers Markets for Years 2009, 2013
      & 2018 (includes corresponding Graph/Chart)                       II-84


 III. MARKET

  1. THE UNITED STATES                                                  III-1
      A.Market Analysis                                                 III-1
        Current & Future Analysis                                       III-1
        Market Overview                                                 III-1
        Select Key Statistics                                           III-1
         Table 10: Number of Nanotechnology Submissions to CDER by
         Platform and Application (includes corresponding
         Graph/Chart)                                                   III-1

         Table 11: Nanotechnology Submissions to CDER by Platform:
         Percentage Breakdown of Number of Submissions for
         Liposomes, Nanoparticles, Nanocrystals, Micelles, SPIO and
         Others (includes corresponding Graph/Chart)                    III-2

         Table 12: Nanotechnology Submissions to CDER by
         Indication/Application: Percentage Breakdown of Number of
         Submissions for Oncology, Pain Management, Infectious
         Diseases, MRI, Immunosuppression and Others (includes
         corresponding Graph/Chart)                                     III-2

         Table 13: Nanotechnology Submissions to CDER by Route of
         Administration: Breakdown of Number of Submissions for
         Intravascular, Inhalation, Oral, Topical and Other
         Injections (includes corresponding Graph/Chart)                III-3

         Table 14: Liposomal Formulation-Based Submissions to CDER
         by Route of Administration: Breakdown of Number of
         Submissions for Intravascular, Inhalation, Oral and Other
         Injections (includes corresponding Graph/Chart)                III-3

         Table 15: Nanoparticle Formulation-Based Submissions to
         CDER by Route of Administration: Breakdown of Number of
         Submissions for Intravascular, Oral, Inhalation, Topical
         and Other Injections (includes corresponding Graph/Chart)      III-3
        FDA’s Regulatory Approach to Nanotechnology Products            III-4
         Regulatory Evolution of Nanomedicine in the US                 III-4
         The Perils of Current Regulatory Status on Nanostructures      III-4
          Few Challenges Faced by FDA                                   III-5
        Competition                                                     III-5
         Overview of Select Key US Nanomedicine Companies Focused on
          Nano Drug Delivery                                            III-5
        Strategic Corporate Developments                                III-6
        Select Players                                                  III-13
      B.Market Analytics                                                III-17
        Table 16: US Recent Past, Current & Future Analysis for
        Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-17

  2. CANADA                                                             III-18
      A.Market Analysis                                                 III-18
        Current & Future Analysis                                       III-18
        Key Player                                                      III-18
      B.Market Analytics                                                III-19
        Table 17: Canadian Recent Past, Current & Future Analysis
        for Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-19

  3. JAPAN                                                              III-20
      A.Market Analysis                                                 III-20
        Current & Future Analysis                                       III-20
        Nanomedicines in Japan - An Overview                            III-20
         List of Select Nanomedicines Approved in Japan                 III-20
        Regulations on Nanomedicine in Japan                            III-20
        Strategic Corporate Developments                                III-21
        Key Player                                                      III-22
      B.Market Analytics                                                III-22
        Table 18: Japanese Recent Past, Current & Future Analysis
        for Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-22

  4. EUROPE                                                             III-23
      A.Market Analysis                                                 III-23
        Current & Future Analysis                                       III-23
        The Rise of Nanotechnology Based Drug Delivery in Europe        III-23
        EU Gears Up for Clarity on Nanomedicine Regulations             III-23
        Harmonization of Regulations - A Key Goal for EMA               III-24
      B.Market Analytics                                                III-25
        Table 19: European Recent Past, Current & Future Analysis
        for Nanotechnology in Drug Delivery by Geographic Region -
        France, Germany, Italy, UK, Spain, Russia and Rest of Europe
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2009 through 2018 (includes
        corresponding Graph/Chart)                                      III-25

        Table 20: European 10-Year Perspective for Nanotechnology in
        Drug Delivery by Geographic Region - Percentage Breakdown of
        Dollar Sales for France, Germany, Italy, UK, Spain, Russia
        and Rest of Europe Markets for Years 2009, 2013 & 2018
        (includes corresponding Graph/Chart)                            III-26

  4a. FRANCE                                                            III-27
      A.Market Analysis                                                 III-27
        Current & Future Analysis                                       III-27
        Nanotechnology and Nanomedicine in France - An Overview         III-27
         Overview of Select Major French Nanomedicine Companies
          Focused on Drug Delivery                                      III-27
        Regulations on Nanomaterials                                    III-28
        Strategic Corporate Developments                                III-29
        Key Player                                                      III-29
      B.Market Analytics                                                III-30
        Table 21: French Recent Past, Current & Future Analysis for
        Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-30

  4b. GERMANY                                                           III-31
      A.Market Analysis                                                 III-31
        Current & Future Analysis                                       III-31
        Germany - A Regional Hub for Nanomedicine Research              III-31
         Overview of Select Major German Nanomedicine Companies
          Focused on Nano Drug Delivery                                 III-31
        Strategic Corporate Development                                 III-32
        Key Players                                                     III-32
      B.Market Analytics                                                III-33
        Table 22: German Recent Past, Current & Future Analysis for
        Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-33

  4c. ITALY                                                             III-34
       Market Analysis                                                  III-34
        Table 23: Italian Recent Past, Current & Future Analysis for
        Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-34

  4d. THE UNITED KINGDOM                                                III-35
      A.Market Analysis                                                 III-35
        Current & Future Analysis                                       III-35
        UK Bets on Advancing Nanotechnology                             III-35
        Strategic Corporate Developments                                III-35
        Key Player                                                      III-37
      B.Market Analytics                                                III-38
        Table 24: UK Recent Past, Current & Future Analysis for
        Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-38

  4e. SPAIN                                                             III-39
       Market Analysis                                                  III-39
        Table 25: Spanish Recent Past, Current & Future Analysis for
        Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-39

  4f. RUSSIA                                                            III-40
       Market Analysis                                                  III-40
        Table 26: Russian Recent Past, Current & Future Analysis for
        Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-40

  4g. REST OF EUROPE                                                    III-41
      A.Market Analysis                                                 III-41
        Current & Future Analysis                                       III-41
        Strategic Corporate Developments                                III-41
        Key Players                                                     III-42
      B.Market Analytics                                                III-44
        Table 27: Rest of Europe Recent Past, Current & Future
        Analysis for Nanotechnology in Drug Delivery Market -
        Analyzed with Annual Sales Figures in US$ Million for Years
        2009 through 2018 (includes corresponding Graph/Chart)          III-44

  5. ASIA-PACIFIC                                                       III-45
       Market Analysis                                                  III-45
        Table 28: Asia-Pacific Recent Past, Current & Future
        Analysis for Nanotechnology in Drug Delivery by Geographic
        Region - China and Rest of Asia-Pacific Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2009 through 2018 (includes corresponding
        Graph/Chart)                                                    III-45

        Table 29: Asia-Pacific 10-Year Perspective for
        Nanotechnology in Drug Delivery by Geographic Region -
        Percentage Breakdown of Dollar Sales for China and Rest of
        Asia-Pacific Markets for Years 2009, 2013 & 2018 (includes
        corresponding Graph/Chart)                                      III-46

  5a. CHINA                                                             III-47
      A.Market Analysis                                                 III-47
        Current & Future Analysis                                       III-47
        New Findings Reinforce Role of Silica Nanoparticles in Drug
         Delivery and Diagnostics                                       III-47
        Nanotechnology Patent Profile in China                          III-47
         Table 30: Number of Patents filed for Nanotechnology-based
         Drug Delivery in China by Country (includes corresponding
         Graph/Chart)                                                   III-48
      B.Market Analytics                                                III-48
        Table 31: Chinese Recent Past, Current & Future Analysis for
        Nanotechnology in Drug Delivery Market - Analyzed with
        Annual Sales Figures in US$ Million for Years 2009 through
        2018 (includes corresponding Graph/Chart)                       III-48

  5b. REST OF ASIA-PACIFIC                                              III-49
      A.Market Analysis                                                 III-49
        Current & Future Analysis                                       III-49
        Indian Nanotechnology Market - An Overview                      III-49
         Nanotechnology to Spur Indian Pharmaceutical Industry          III-49
         Major Players                                                  III-49
        Strategic Corporate Developments                                III-50
        Key Player                                                      III-52
      B.Market Analytics                                                III-53
        Table 32: Rest of Asia-Pacific Recent Past, Current & Future
        Analysis for Nanotechnology in Drug Delivery Market -
        Analyzed with Annual Sales Figures in US$ Million for Years
        2009 through 2018 (includes corresponding Graph/Chart)          III-53

  6. LATIN AMERICA                                                      III-54
       Market Analysis                                                  III-54
        Table 33: Latin American Recent Past, Current & Future
        Analysis for Nanotechnology in Drug Delivery Market -
        Analyzed with Annual Sales Figures in US$ Million for Years
        2009 through 2018 (includes corresponding Graph/Chart)          III-54

  7. REST OF WORLD                                                      III-55
      A.Market Analysis                                                 III-55
        Current & Future Analysis                                       III-55
        Strategic Corporate Development                                 III-55
      B.Market Analytics                                                III-56
        Table 34: Rest of World Recent Past, Current & Future
        Analysis for Nanotechnology in Drug Delivery Market -
        Analyzed with Annual Sales Figures in US$ Million for Years
        2009 through 2018 (includes corresponding Graph/Chart)          III-56


 IV. COMPETITIVE LANDSCAPE

     Total Companies Profiled: 60 (including Divisions/Subsidiaries - 60)

     The United States (28)
     Canada (2)
     Japan (3)
     Europe (16)
     - France (4)
     - Germany (3)
     - The United Kingdom (5)
     - Rest of Europe (4)
     Asia-Pacific (Excluding Japan) (10)
     Middle East (1)

 

 

Additional Information:
This report is offered in PDF format via e-mail. Once downloaded, the PDF can’t be copied to another computer. The user is permitted to print one full copy of the report. Extra copies or licenses may be purchased at 10% of the list price.
Date of Publication:
Feb 13, 2014
File Format:
PDF via E-mail
Number of Pages:
202 Pages
Type the characters you see in the picture above.